Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Liquidia Corp

NASDAQ: LQDA · Life Sciences · 16 alerts · CIK 1819576

Share price
$56.37Close, Nov 16
Market cap
$5.08B
Shares outstanding
90.11MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Liquidia Corp filings on SEC EDGAR ↗

6:03 AM ET 8-K
Court & Legal Update

Liquidia Court & Legal Update

Liquidia Corporation entered into a global settlement agreement with United Therapeutics to resolve all ongoing patent infringement, trade secret, and antitrust litigation. Liquidia will make aggregate payments of $320.4 million to UTC ($175M net initial payment plus $145.4M in 2027 installments) while agreeing to remove the PH-ILD indication from its YUTREPIA label to maintain the product's availability for PAH patients.

Counterparty
United Therapeutics Corporation

“Today’s agreement fully resolves years of litigation and provides certainty to PAH patients that they can continue to access YUTREPIA, whose differentiated attributes have enabled its rapid adoption by physicians and patients since launch.”

Dr. Roger Jeffs, CEO
5:27 PM ET 8-K
Court & Legal Update

Liquidia Court & Legal Update

The U.S. District Court for the District of Delaware ruled that Liquidia's lead product, YUTREPIA, infringed on two valid claims of United Therapeutics' '327 patent. Liquidia intends to appeal the decision and may seek to remove the PH-ILD indication from its label to mitigate potential injunctive relief that could restrict the product's market availability.

Counterparty
United Therapeutics Corporation

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.